The critical role of Sirt1 in ischemic stroke

Ziyi Jia, Ke Xu, Ruobing Li, Siyu Yang, Long Chen, Qianwen Zhang, Shulin Li, Xiaowei SunFrontiers in Pharmacology 2025 · DOI

Abstract

Ischemic stroke, the most prevalent form of stroke, is responsible for the highest disability rates globally and ranks as the primary cause of mortality worldwide. Sirt1, extensively investigated in neurodegenerative disorders, is the most well-known and earliest member of the sirtuins family. However, its mechanism of action during ischemic stroke remains ambiguous. The literature examination revealed the intricate involvement of Sirt1 in regulating both physiological and pathological mechanisms during ischemic stroke. Sirt1 demonstrates deacetylation effects on PGC-1α, HMGB1, FOXOs, and p53. It hinders the activation of NLRP3 inflammasome and NF-κB while also engaging with AMPK. It regulates inflammatory response, oxidative stress, mitochondrial dysfunction, autophagy, pro-death, and necrotic apoptosis. Therefore, the potential of Sirt1 as a therapeutic target for the management of ischemic stroke is promising.

Introduction

Ischemic stroke, resulting from a sudden blockage in cerebral blood flow, remains a leading cause of global mortality and long-term disability. While current clinical interventions like thrombolysis can restore perfusion, they are limited by a narrow therapeutic window and the risk of "reperfusion injury," where the reintroduction of oxygen triggers a secondary wave of molecular damage. There is a critical need for neuroprotective therapies that can stabilize brain tissue at the cellular level. Sirt1, a NAD+-dependent deacetylase, has emerged as a central hub in the brain's defense against ischemic injury, acting as a master molecular switch to regulate survival pathways.

Key Mechanisms of Sirt1 Neuroprotection

Sirt1 exerts its protective effects by deacetylating a wide array of target proteins, managing several distinct pathological axes simultaneously.

Regulating the Neuroinflammatory Response

One of Sirt1's primary roles is acting as a "brake" on inflammation. By removing acetyl groups from the p65 subunit of NF-κB, Sirt1 effectively shuts down the production of proinflammatory cytokines. Additionally, it prevents the translocation of HMGB1—a major danger signal—from the nucleus to the cytoplasm, thereby averting a massive systemic immune response and the activation of the NLRP3 inflammasome.

Sirt1-mediated regulation of neuroinflammatory pathways, including the inhibition of NF-κB and the NLRP3 inflammasome.

Strengthening the Antioxidant Shield

During the reperfusion phase of a stroke, neurons are subjected to an "oxidative burst." Sirt1 counters this by activating PGC-1α and Nrf2, the cell's primary drivers for producing antioxidant enzymes like Superoxide Dismutase (SOD) and Catalase (CAT). This pathway helps neutralize reactive oxygen species (ROS) and preserves cellular integrity under extreme stress.

Sirt1 promotes antioxidant defense by deacetylating PGC-1α, Nrf2, and FOXOs, leading to increased production of SOD and CAT.

Mitochondrial Quality Control and Autophagy

Beyond inflammation and oxidation, Sirt1 is vital for maintaining energy production. Through the Sirt1/PGC-1α/TFAM pathway, it promotes mitochondrial biogenesis, ensuring neurons can produce ATP despite ischemic stress. Furthermore, Sirt1 regulates autophagy to maintain a "Goldilocks" zone—clearing out damaged organelles without triggering excessive self-digestion that could lead to cell death.

Therapeutic Potential and Key Findings

Review of current literature highlights several consistent trends in Sirt1 research:

  • Reduction in Infarct Volume: In animal models like Middle Cerebral Artery Occlusion (MCAO), Sirt1 activators such as Resveratrol significantly reduce the area of dead brain tissue and improve neurological scores.
  • Blood-Brain Barrier (BBB) Integrity: Sirt1 helps maintain the BBB by regulating tight junction proteins, preventing the infiltration of harmful systemic immune cells.
  • Neurogenesis: Sirt1 expression in neural stem cells promotes their differentiation into functional neurons, suggesting a potential role in long-term functional recovery.

Challenges and Future Directions

Despite its therapeutic promise, several hurdles remain for clinical translation. Many potent Sirt1 activators have poor bioavailability and difficulty crossing the human blood-brain barrier. Furthermore, the subcellular complexity of Sirt1—where its role may differ between the nucleus and cytoplasm—requires more precise spatial-temporal research. Future work must focus on large-scale human clinical trials and the development of more bioavailable pharmacological modulators to bridge the gap between animal models and patient care.

Conclusion

Sirt1 stands as a premier candidate for future stroke therapies due to its multi-modal ability to dampen neuroinflammation, neutralize oxidative stress, and preserve mitochondrial function. As a master regulator of cellular survival, Sirt1 offers a promising target for mitigating the devastating impact of ischemic stroke.

Summary updated

Abstract

Ischemic stroke, the most prevalent form of stroke, is responsible for the highest disability rates globally and ranks as the primary cause of mortality worldwide. Sirt1, extensively investigated in neurodegenerative disorders, is the most well-known and earliest member of the sirtuins family. However, its mechanism of action during ischemic stroke remains ambiguous. The literature examination revealed the intricate involvement of Sirt1 in regulating both physiological and pathological mechanisms during ischemic stroke. Sirt1 demonstrates deacetylation effects on PGC-1α, HMGB1, FOXOs, and p53. It hinders the activation of NLRP3 inflammasome and NF-κB while also engaging with AMPK. It regulates inflammatory response, oxidative stress, mitochondrial dysfunction, autophagy, pro-death, and necrotic apoptosis. Therefore, the potential of Sirt1 as a therapeutic target for the management of ischemic stroke is promising.
BibTeX
@inproceedings{jia2025critical,
  author = {Ziyi Jia and Ke Xu and Ruobing Li and Siyu Yang and Long Chen and Qianwen Zhang and Shulin Li and Xiaowei Sun},
  title = {{The critical role of Sirt1 in ischemic stroke}},
  booktitle = {Frontiers in Pharmacology},
  year = {2025},
  doi = {10.3389/fphar.2025.1425560},
}
Figure